CN Patent

CN105102457A — {4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式

Assigned to Bayer Pharma AG · Expires 2015-11-25 · 10y expired

What this patent protects

本发明涉及{4.6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3.4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式，包括它的变体I、变体II、单-DMSO溶剂合物、倍半-DMSO溶剂合物和1/4-乙酸乙酯溶剂合物。

USPTO Abstract

本发明涉及{4.6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3.4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式，包括它的变体I、变体II、单-DMSO溶剂合物、倍半-DMSO溶剂合物和1/4-乙酸乙酯溶剂合物。

Drugs covered by this patent

Adempas (RIOCIGUAT) · Bayer

Patent Metadata

Patent number: CN105102457A
Jurisdiction: CN
Classification: —
Expires: 2015-11-25
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Pharma AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.